Search companies

Live

ANTERIS TECHNOLOGIES GLOBAL CORP. (ASX: AVR)

Health care · News and insights

Price unavailable

Latest AVR announcements

Announcement Insights

Anteris Advances PARADIGM Trial as Quarterly Cash Outflow Reaches US$23 Million

Anteris reported approximately US$23 million in operating cash outflows for the September quarter, principally supporting clinical, regulatory and manufacturing work as enrolment in its PARADIGM trial progressed. Regulatory clearances and approvals after quarter-end extended the study into Germany and Australia, while a Minnesota facility is intended to expand production capacity ahead of potential commercialisation. Separately, 30-day results from 22 EMBARK study patients showed improved valve-opening measures and lower pressure gradients for the medium DurAVR valve; it remains investigational.

Updated 11 Nov 2026, 09:43 AM Sydney time
Share
SourcesQuarterly Results Announcement and SEC Form 10-QResults for the Third Quarter of 2026Filing of Amendments to Form 10-K and Forms 10-QNotice of Annual General Meeting/Proxy FormStatement of CDIs on issue - AVRNotification of cessation of securities - AVRMedium-Size DurAVR THV Outcomes - Embark StudySchedule 14A Preliminary Proxy Statement
Comments

Anteris Advances PARADIGM Trial as Quarterly Cash Outflow Reaches US$23 Million

2026-11-11 · Health care

AVR: $8.50 +0.00% · MC: $876M

Anteris reported net operating cash outflows of approximately US$23 million for the September quarter, mainly supporting clinical, regulatory and manufacturing work on its PARADIGM trial. Trial enrolment is progressing across active sites, with regulatory clearance and approvals after quarter-end extending the study into Germany and Australia; the company also took occupancy of a Minnesota facility intended to expand production capacity ahead of potential commercialisation.

Updated 2026-11-11 09:28
Share
SourcesQuarterly Results Announcement and SEC Form 10-QResults for the Third Quarter of 2026
Comments

Anteris Amends US Filings to Add Omitted Financial Control Language

2026-11-10 · Health care

AVR: $8.50 +3.03% · MC: $876M

Anteris Technologies Global Corp. has amended its annual and quarterly US filings to add omitted language about internal controls over financial reporting to its chief executive and chief financial officer certifications. The company said the amendments do not change its previously reported financial statements or results. Separately, Anteris filed its definitive proxy statement for its December annual meeting, following a preliminary filing in October. The meeting will be held in Sydney and online, with CDI holders required to direct their votes in advance.

Updated 2026-11-10 15:19
Share
SourcesFiling of Amendments to Form 10-K and Forms 10-QNotice of Annual General Meeting/Proxy Form
Comments

Anteris Reports Net Transfer of CDIs to Nasdaq Stock

2026-11-06 · Health care

AVR: $8.20 -4.21% · MC: $876M

Anteris Technologies Global Corp. reported a net transfer of approximately 60,000 securities from ASX-listed depositary interests into Nasdaq common stock during October. The number of depositary interests fell to approximately 14 million, while common stock increased by the same amount to approximately 83 million.

Updated 2026-11-06 10:32
Share
SourcesStatement of CDIs on issue - AVR
Comments

Anteris Reports Lapse Of Restricted Stock Units And Options

2026-11-05 · Health care

AVR: $8.56 +6.07% · MC: $876M

Anteris Technologies Global Corp. reported that restricted stock units and options lapsed after their conditions were not met or became incapable of being satisfied. The cessation covered several batches of securities, including both employee-style units and options.

Updated 2026-11-05 13:53
Share
SourcesNotification of cessation of securities - AVR
Comments

Anteris Reports Early DurAVR Heart Valve Study Results

2026-11-02 · Health care

AVR: $9.15 +3.62% · MC: $876M

Anteris Technologies Global Corp. reported no valve-related deaths or moderate or severe leaks one month after treatment in a small study of its medium-size DurAVR heart valve. The study also found no moderate or severe mismatch between the valve opening and patients’ blood-flow needs. A larger randomised trial comparing DurAVR with commercially available valves is enrolling patients.

Updated 2026-11-02 15:32
Share
SourcesMedium-Size DurAVR THV Outcomes - Embark Study
Comments

Anteris Sets December Date For 2026 Annual Meeting

2026-10-29 · Health care

AVR: $8.55 +1.18% · MC: $876M

Anteris Technologies Global Corp. has filed a preliminary proxy statement for its 2026 annual meeting, scheduled for December 2 in the US (December 3 in Australia), with in-person and webcast attendance available. The company expects to send the definitive proxy statement around November 9 in the US (November 10 in Australia); the preliminary filing remains subject to change.

Updated 2026-10-29 11:04
Share
SourcesSchedule 14A Preliminary Proxy Statement
Comments